Drug Efficacy And SafetyEnliven's CML drug remains ahead of peers with better data and differentiated mechanism of action to capture earlier line patients.
Investment RecommendationThe analyst's recommendation is a 'Buy' for Enliven Therapeutics, Inc.
Market PositioningEmerging resistance mutations with Scemblix negatively impact its efficacy, but ELVN-001 retains efficacy, presenting a clear opportunity due to its best-in-class efficacy and safety profile.